Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment

Lot A. Devriese,Petronella O. Witteveen,Serena Marchetti,Marja Mergui-Roelvink,Larisa Reyderman,Jantien Wanders,A. Jenner,G. Edwards,Jos H. Beijnen,Emile E. Voest,Jan H. M. Schellens

Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment

2012

Lot A. Devriese
Petronella O. Witteveen
Serena Marchetti
Marja Mergui-Roelvink
Larisa Reyderman
Jantien Wanders
A. Jenner
G. Edwards
Jos H. Beijnen
Emile E. Voest
Jan H. M. Schellens

Purpose The aim of this study was to determine the plasma pharmacokinetics of eribulin mesylate in patients with solid tumors with mild and moderate hepatic impairment.

Keywords:

Pharmacology
Eribulin Mesylate
Hepatic impairment
Medicine
Pharmacokinetics
in patient
pharmacology toxicology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations